Paying users zone. Data is hidden behind 
.
Get 1-month access to Bristol-Myers Squibb Co. for $17.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Bristol-Myers Squibb Co. (BMY)
Statement of Comprehensive Income
Low level of difficulty
Comprehensive income is the change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owners sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
Bristol-Myers Squibb Co., consolidated statement of comprehensive income
US$ in millions
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
| Comprehensive income item | Description | The company |
|---|---|---|
| Net earnings attributable to BMS | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | Bristol-Myers Squibb Co.’s net earnings attributable to BMS declined from 2016 to 2017 but then increased from 2017 to 2018 exceeding 2016 level. |
| Comprehensive income attributable to BMS | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. | Bristol-Myers Squibb Co.’s comprehensive income attributable to BMS declined from 2016 to 2017 but then increased from 2017 to 2018 exceeding 2016 level. |